Redefining Treatment Paradigms in First-line Advanced Non-Small-Cell Lung Cancer

被引：13

作者：

Heigener, David F. ^{[1
,2
,3
]}

Kerr, Keith M. ^{[4
]}

Laing, Gavin M. ^{[4
]}

Mok, Tony S. K. ^{[5
]}

Moiseyenko, Fedor V. ^{[6
,7
]}

Reck, Martin ^{[3
,8
,9
]}

机构：

[1] Helios Klinikum Schleswig, Dept Pulmonol, Schleswig, Germany

[2] Univ Kiel, Kiel, Germany

[3] Airway Res Ctr North German Ctr Lung Res DZL, Grosshansdorf, Germany

[4] Aberdeen Royal Infirm, Dept Pathol, Aberdeen, Scotland

[5] Chinese Univ Hong Kong, Fac Med, Hong Kong, Peoples R China

[6] Inst Oncol NN Petrov St Petersburg, Pesochny, Russia

[7] St Petersburg City Canc Ctr, St Petersburg, Russia

[8] LungenClin Grosshansdorf, Grosshansdorf, Germany

[9] Univ Lubeck, Lubeck, Germany

来源：

CLINICAL CANCER RESEARCH | 2019年 / 25卷 / 16期

关键词：

PLATINUM-BASED CHEMOTHERAPY; DABRAFENIB PLUS TRAMETINIB; OPEN-LABEL; EGFR MUTATIONS; INTERNATIONAL ASSOCIATION; PHASE-III; AFATINIB; MULTICENTER; CRIZOTINIB; GEFITINIB;

D O I：

10.1158/1078-0432.CCR-18-1894

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Metastatic non-small-cell lung cancer is still a devastating disease; however, treatment options have diversified dramatically in the past two decades. From unselected platinum-based chemotherapy for all patients, several different treatment groups have evolved, that is, those with "druggable" targets, those with a promising immune signature, and those without any predicting factors outlined in this article. Challenge includes the intersections between these groups and the optimal treatment path. These issues will be addressed in this review.

引用

页码：4881 / 4887

页数：7

共 50 条

[41] Achieving Response and Improving Outcomes of First-line Therapy for Advanced Non-small-cell Lung Cancer
Loh, K. K.
HONG KONG JOURNAL OF RADIOLOGY, 2013, 16 (04): : S23 - S28
[42] Bevacizumab as first-line therapy in advanced non-small-cell lung cancer: A Brazilian center experience
Jardim D.L.F.
De Melo Gagliato D.
Ribeiro K.B.
Shimada A.K.
Katz A.
Drugs in R&D, 2012, 12 (4) : 207 - 216
[43] Efficacy and safety of icotinib as first-line therapy in patients with advanced non-small-cell lung cancer
Shen, Yan-Wei
Zhang, Xiao-Man
Li, Shu-Ting
Lv, Meng
Yang, Jiao
Wang, Fan
Chen, Zhe-Ling
Wang, Bi-Yuan
Li, Pan
Chen, Ling
Yang, Jin
ONCOTARGETS AND THERAPY, 2016, 9 : 929 - 935
[44] TKI as First Line Treatment in Advanced Non-Small-Cell Lung Cancer with EGFR Mutations
Guerreiro, Ines
Silva, Ana Vitor
Rodrigues, Ana
Oliveira, Cristina
Pousa, Ines
Oliveira, Julio
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1244 - S1245
[45] Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancer
Reck, Martin
IMMUNOTHERAPY, 2018, 10 (02) : 93 - 105
[46] What Is the Standard First-Line Treatment for Advanced Non-Small Cell Lung Cancer?
Ricciuti, Biagio
Awad, Mark M.
CANCER JOURNAL, 2020, 26 (06): : 485 - 495
[47] First-line treatment for non-small cell lung cancer
Pinn, Stephen
BRITISH JOURNAL OF HOSPITAL MEDICINE, 2011, 72 (01) : 10 - 10
[48] First-Line Dual Immunotherapy, a Treatment Option in First-Line Metastatic Non-Small-Cell Lung Cancer: Are We Ready to Use It?
Uprety, Dipesh
Remon, Jordi
Peters, Solange
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (04)
[49] EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer
Nan, Xueli
Xie, Chao
Yu, Xueyan
Liu, Jie
ONCOTARGET, 2017, 8 (43) : 75712 - 75726
[50] Cisplatin plus vinorelbine as first-line treatment for advanced non-small-cell lung cancer: Is a hemogram on day 8 essential?
Provencio, Mariano
de Las Penas, Ramon
Camps, Carlos
Artal, Angel
Massuti, Bartomeu
Cobo, Manuel
Javier Perez, Francisco
Sanchez, Antonio
Rosell, Rafael
LUNG CANCER, 2010, 68 (03) : 415 - 419

← 1 2 3 4 5 →